Page 1

Verastem Oncology Verastem Oncology Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress May 11 , 2021 Updated Phase 1/2 Data in Recurrent Low - Grade Serous Ovarian Cancer ( LGSOC ) Continues to Demonstrate Activity , Durability and a Favorable Tolerability Profile for VS - 6766 + Defactinib Combination Two Registration - Directed Phase 2 Trials Underway in LGSOC and KRAS G12V Non - Small Cell Lung Cancer with Multiple Key Catalysts Expected in 1H 2022 BOSTON -- ( BUSINESS WIRE ) -- May 11 , 2021-- Verastem , Inc. ( Nasdaq : VSTM ) ( also known as Verastem Oncology ) , a biopharmaceutical company committed to advancing new medicines for patients battling cancer , today reported financial results for the three months ended March 31 , 2021 , highlighted recent progress and outlined key corporate objectives . " During the first quarter of 2021 , we expanded the selection portion of the Phase 2 RAMP 201 study to include all recurrent low - grade serous ovarian cancer types . This decision was based on the positive updated data from the LGSOC cohort of the Phase 1/2 FRAME which continues to show strong response rates across both KRAS mutant and wild - type recurrent LGSOC , along with robust durability and a favorable tolerability profile , " said Brian Stuglik , Chief Executive Officer of Verastem Oncology . " We closed the first quarter with just over $ 127 million in cash , cash equivalent and investments , leaving us well positioned to execute on our two ongoing Phase 2 studies evaluating VS - 6766 and defactinib in LGSOC and KRAS G12V non - small cell lung cancer ( NSCLC ) , as well as our other key corporate objectives . " Recent Corporate Highlights LGSOC • Reported updated data from the LGSOC cohort of the ongoing , investigator - sponsored Phase 1/2 FRAME study evaluating VS - 6766 in combination with defactinib in patients with recurrent LGSOC . Combination continues to demonstrate activity , durability and a favorable tolerability profile , including in patients who have progressed following treatment with a MEK inhibitor . • Overall response rate ( ORR ) across all patients was 52 % ( 11 of 21 patients ) . • ORR for patients with KRAS mutant LGSOC was 70 % ( 7 of 10 patients ) . • ORR for patients with wild type LGSOC was 44 % ( 4 of 9 patients ) . o The most common side effects were Grade 1/2 rash , creatine kinase elevation , nausea , hyperbilirubinemia and diarrhea , which were reversible . • Company - sponsored , registration - directed Phase 2 study ( RAMP 201 ) underway investigating VS - 6766 alone and in combination with defactinib for the treatment of recurrent LGSOC . Study recently expanded to include both KRAS mutant and KRAS wild - type patients in the selection phase to determine the optimal go - forward regimen for both types of LGSOC . KRAS G12V Mutant NSCLC • Company - sponsored , registration - directed Phase 2 study ( RAMP 202 ) underway investigating VS - 6766 alone and in combination with defactinib for the treatment of patients with KRAS G12V mutant NSCLC . Upcoming Milestones and Key Priorities for 2021-2022 LGSOC • Updated data from Phase 1/2 FRAME study to be submitted for presentation at a major medical meeting during the second half of 2021 . • Complete selection portion of RAMP 201 during first half of 2022 ; commence expansion portion . G12V NSCLC • Complete selection portion of RAMP 202 during first half of 2022 ; commence expansion portion . First Quarter 2021 Financial Results